What is it about?
A retrospective comparison of the use of EPO vs standard transfusion in infants with hereditary spherocytosis
Featured Image
Why is it important?
It shows a clinical and economic advantage of using EPO in young children affecet by hereditary spherocytosis
Perspectives
Read the Original
This page is a summary of: Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (Associazione Italiana Emato-Oncologia Pediatrica), American Journal of Hematology, April 2017, Wiley,
DOI: 10.1002/ajh.24713.
You can read the full text:
Contributors
The following have contributed to this page